Tremfya & Skyrizi in psoriasis patients with HIV

[Fred]

This retrospective cohort study evaluated the clinical outcomes of HIV-positive patients undergoing anti-IL-23 therapy in real-world settings at the Dermatology Units of four leading reference centres in Northern Italy for the treatment of psoriasis.

Quote:

---

HIV-positive patients with psoriasis often face delays in accessing biologic therapies due to their exclusion from clinical trials and concerns about the impact of immunomodulatory drugs on viral replication.

Anti-IL-23 therapies, such as risankizumab and guselkumab, have shown great promise thanks to their strong efficacy and favourable safety profiles.

A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis.

Source: onlinelibrary.wiley.com

*Funding: The authors received no specific funding for this work.

[post=115641]

[post=167169]